Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

NCT04050436 is registered in ClinicalTrials.gov with Replimune, Inc. as lead sponsor.

NCT NCT04050436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04050436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Lead sponsor
Replimune, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 8, 2019
Completion date
September 30, 2025
Enrollment
231 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma, metastatic cutaneous squamous cell carcinoma